US 12,385,904 B2
Method of detecting inflammation
Etheresia Pretorius, Stellenbosch (ZA); Douglas Bruce Kell, Manchester (GB); and Willem Johan Simon De Villiers, Stellenbosch (ZA)
Assigned to Stellenbosch University, Stellenbosch (ZA)
Appl. No. 16/763,470
Filed by Stellenbosch University, Stellenbosch (ZA)
PCT Filed Nov. 13, 2018, PCT No. PCT/IB2018/058903
§ 371(c)(1), (2) Date May 12, 2020,
PCT Pub. No. WO2019/092677, PCT Pub. Date May 16, 2019.
Claims priority of application No. 1718704 (GB), filed on Nov. 13, 2017.
Prior Publication US 2020/0363403 A1, Nov. 19, 2020
Int. Cl. G01N 3/50 (2006.01); G01N 33/50 (2006.01); G01N 33/564 (2006.01)
CPC G01N 33/5091 (2013.01) [G01N 33/5008 (2013.01); G01N 33/564 (2013.01); G01N 2800/52 (2013.01)] 13 Claims
 
1. A method of detecting and treating inflammation in a subject, the inflammation indicating cancer, the method comprising the steps of:
determining a quantity of amyloid present in fibrin clots in a blood sample obtained from the subject by contacting the blood sample with an amyloid-binding fluorescent marker and measuring fluorescence emitted upon binding of amyloid to the fluorescent marker;
determining a concentration of serum amyloid A (SAA) in the blood sample, wherein the concentration of SAA is determined using an enzyme-linked immunosorbent assay (ELISA);
determining inflammation in the subject if both the quantity of amyloid in the blood sample is greater than a threshold level, the threshold level being 2 times a predetermined blood level of amyloid associated with a healthy subject without inflammation and the concentration of SAA is greater than 30 micrograms/ml; and
administering an effective amount of a treatment for reducing the determined inflammation or for treating cancer to the subject, wherein the treatment is chemotherapy or immunotherapy.